Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer : A population-based study in Sweden

Ji, Jianguang LU orcid ; Sundquist, Jan LU and Sundquist, Kristina LU (2018) In International Journal of Cancer 142(10). p.2003-2010
Abstract

The association between hormone therapy (estrogen, with or without progesterone) and colorectal cancer (CRC) has received considerable scientific interest but previous research has generated inconsistent results. We aimed to examine whether post-diagnostic use of hormone therapy might protect against CRC mortality and all-cause mortality. Women diagnosed with CRC between January 2007 and December 2012 were identified from the Swedish Cancer Registry and linked to the Swedish Prescribed Drug Register to retrieve hormone therapy users after CRC diagnosis. A total of 1,109 patients were diagnosed with CRC and used hormone therapy post-CRC diagnosis. Time-dependent Cox regression with 1-year lag was used to calculate the hazard ratio (HR)... (More)

The association between hormone therapy (estrogen, with or without progesterone) and colorectal cancer (CRC) has received considerable scientific interest but previous research has generated inconsistent results. We aimed to examine whether post-diagnostic use of hormone therapy might protect against CRC mortality and all-cause mortality. Women diagnosed with CRC between January 2007 and December 2012 were identified from the Swedish Cancer Registry and linked to the Swedish Prescribed Drug Register to retrieve hormone therapy users after CRC diagnosis. A total of 1,109 patients were diagnosed with CRC and used hormone therapy post-CRC diagnosis. Time-dependent Cox regression with 1-year lag was used to calculate the hazard ratio (HR) of CRC mortality and all-cause mortality associated with post-diagnostic use of hormone therapy. Use of hormone therapy after CRC diagnosis was associated with a 26% risk reduction in CRC mortality (HR = 0.67, 95%CI 0.56–0.79) and a 30% risk reduction in all-cause mortality (HR = 0.68, 95%CI 0.59–0.77). The risk reduction was even stronger if women also used hormone therapy before the diagnosis of CRC and for women with higher cumulative doses of hormone therapy. The risk reduction was largely consistent irrespective of CRC severity. Our data suggests that use of hormone therapy after CRC diagnosis is associated with a decreased risk of cancer-related mortality and all-cause mortality.

(Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
all-cause mortality, cause-specific mortality, colorectal cancer, hormone therapy
in
International Journal of Cancer
volume
142
issue
10
pages
8 pages
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:29270993
  • scopus:85044372731
ISSN
0020-7136
DOI
10.1002/ijc.31228
language
English
LU publication?
yes
id
7d04cd3e-96be-4fe0-9d40-bb5e407b1a05
date added to LUP
2018-04-04 11:04:35
date last changed
2024-06-25 15:02:38
@article{7d04cd3e-96be-4fe0-9d40-bb5e407b1a05,
  abstract     = {{<p>The association between hormone therapy (estrogen, with or without progesterone) and colorectal cancer (CRC) has received considerable scientific interest but previous research has generated inconsistent results. We aimed to examine whether post-diagnostic use of hormone therapy might protect against CRC mortality and all-cause mortality. Women diagnosed with CRC between January 2007 and December 2012 were identified from the Swedish Cancer Registry and linked to the Swedish Prescribed Drug Register to retrieve hormone therapy users after CRC diagnosis. A total of 1,109 patients were diagnosed with CRC and used hormone therapy post-CRC diagnosis. Time-dependent Cox regression with 1-year lag was used to calculate the hazard ratio (HR) of CRC mortality and all-cause mortality associated with post-diagnostic use of hormone therapy. Use of hormone therapy after CRC diagnosis was associated with a 26% risk reduction in CRC mortality (HR = 0.67, 95%CI 0.56–0.79) and a 30% risk reduction in all-cause mortality (HR = 0.68, 95%CI 0.59–0.77). The risk reduction was even stronger if women also used hormone therapy before the diagnosis of CRC and for women with higher cumulative doses of hormone therapy. The risk reduction was largely consistent irrespective of CRC severity. Our data suggests that use of hormone therapy after CRC diagnosis is associated with a decreased risk of cancer-related mortality and all-cause mortality.</p>}},
  author       = {{Ji, Jianguang and Sundquist, Jan and Sundquist, Kristina}},
  issn         = {{0020-7136}},
  keywords     = {{all-cause mortality; cause-specific mortality; colorectal cancer; hormone therapy}},
  language     = {{eng}},
  month        = {{05}},
  number       = {{10}},
  pages        = {{2003--2010}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{International Journal of Cancer}},
  title        = {{Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer : A population-based study in Sweden}},
  url          = {{http://dx.doi.org/10.1002/ijc.31228}},
  doi          = {{10.1002/ijc.31228}},
  volume       = {{142}},
  year         = {{2018}},
}